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ABSTRACT 
Background & Aims: Spontaneous resolution of hepatitis C virus (HCV) infections depends upon a 
broad T cell response to multiple viral epitopes. Most patients fail to clear infections spontaneously, 
however, and develop chronic disease. The elevated number and function of 
CD3+CD4+CD25+FoxP3+ regulatory T(reg) cells in HCV-infected patients suggest the role of Treg cells in 
impaired viral clearance. The factors contributing to increased Treg cell activity in chronic hepatitis C 
cases remain to be delineated.  
Methods: Immunoinformatics tools were used to predict promiscuous, highly-conserved HLA-DRB1-
restricted immunogenic consensus sequences (ICS), each composed of multiple T cell epitopes. 
These sequences were synthesized and added to cultures of peripheral blood mononuclear cells 
(PBMCs) derived from patients who resolved HCV infection spontaneously, patients with persistent 
infection, and non-infected individuals. The cells were collected following 5 days incubation, 
quantified and characterized by flow cytometry.  
Results: One ICS, HCV_G1_p7_794, induced a marked increase in Treg cells in PBMC cultures 
derived from infected patients, but not patients who spontaneously cleared HCV or non-infected 
individuals. An analogous human peptide (p7_794), on the other hand, induced a significant increase 
in Treg cells among PBMCs derived from both HCV infected and non-infected individuals. JanusMatrix 
analyses determined that HCV_G1_p7_794 is comprised of Treg cell epitopes that exhibit extensive 
cross-reactivity with the human proteome.  
Conclusion:  A virus-encoded peptide (HCV_G1_p7_794) with extensive human homology activates 
cross-reactive CD3+CD4+CD25+FoxP3+ nTreg cells, which potentially contribute to 
immunosuppression and chronic hepatitis C. 
Keywords: hepatitis C; regulatory T cells; cross-reactive; epitope  
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Introduction 
Chronic hepatitis C virus (HCV) infection is a major public health concern worldwide. It is the leading 
cause of liver failure and reason for liver transplant in the US. Irrespective of clinical outcome, acute 
HCV infections are characterized by broad HCV-specific T cell responses that correlate with 
spontaneous viral clearance in a minority of individuals [1]. In most patients, however, this initial 
response fails to contain the virus and chronic disease results. Increased numbers of CD4+ regulatory 
T(reg) cells circulating in the bloodstream and accumulating in the liver have been implicated in the 
pathogenesis of chronic hepatitis C [2,3].   
Treg cells constitute one of the major mechanisms underlying immunological homeostasis and 
self-tolerance [4]. In addition, Treg cells play a key role in moderating the immune response to 
infectious diseases, suppressing host tissue and organ damage that would occur in the absence of 
regulation [5]. Although key to maintaining immune homeostasis, a growing body of evidence 
suggests that Treg cells also contribute to the establishment and persistence of chronic infections, 
e.g., HCV [6,7]. While no single marker exists, human Treg cells are classically identified by 
expression of the transcription factor, forkhead box P3 (FoxP3), and the cell surface expression of the 
interleukin (IL)-2 receptor α chain (CD25).   
Two distinct Treg cell subsets are described in the literature: natural (n)Treg cells specific for self 
epitopes and generated by high-avidity selection in the thymus, and inducible (i)Treg cells that derive 
from conventional (CD4+CD25-FoxP3-) T cells following stimulation in the periphery [8]. nTreg cells can 
induce the conversion of conventional T cells to iTreg cells via cytokine-dependent and -independent 
mechanisms, a process called infectious tolerance [9,10]. Notably, the factors that affect expansion of 
the Treg cell population in cases of chronic hepatitis C remain to be fully delineated. Nonetheless, the 
consensus supports the heterogeneous nature of the expanded Treg cell population composed of both 
nTreg and iTreg cell subsets [11].  
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Here, we describe a unique viral peptide derived from HCV p7 protein (HCV_G1_p7_794) that 
promotes a Treg cell response among PBMCs derived from patients with persistent HCV infection. 
This peptide exhibited human homology when evaluated using GenBank Basic Local Alignment 
Search Tool (BLAST) [12]. Further analysis using a new bioinformatics tool, JanusMatrix [13,14], 
demonstrated that this HCV peptide cross-reacts with HLA matched peptide sequences located 
within hundreds of human proteins. Our data suggest that HCV_G1_p7_794 engages preexisting 
nTreg cells as a consequence of this homology, induces infectious tolerance and the expansion of an 
iTreg cell population, which contributes to suppression of effector T(eff) cell activity in cases of chronic 
HCV infection.   
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Materials and Methods  
Subjects   
HCV-seropositive subjects with persistent viremia (Ab+VL+), patients who spontaneously resolved 
infection (Ab+VL-) and HCV-seronegative, non-infected (Ab-VL-) individuals were recruited from the 
Rhode Island Adult Corrections Institution to participate in this study. Patients with serological 
evidence of co-infection with hepatitis B virus or human immunodeficiency virus, reported history of  
any other immunocompromising condition or prior treatment for HCV were not included. Details of 
recruitment and the population are described elsewhere [15]. PBMC obtained from subjects were 
cryopreserved for use in the investigations presented herein. The Institutional Review Boards of the 
Miriam Hospital, Rhode Island Department of Corrections and Office of Human Research Protection 
approved this study. All HCV infected subjects were infected with HCV genotype 1a or 1b (Versant 
HCV genotype assay2, Siemens Healthcare Diagnostics Inc.).  Hartford Hospital Transplantation 
Research Laboratory (Hartford, CT) performed HLA typing.  Demographic and serologic data are 
shown in Table 1. 
JanusMatrix analysis 
Crystal structure analyses of ternary, MHC:epitope:T cell receptor (TcR) complexes indicate that 
certain amino acid residues of  a T cell epitope contact the MHC molecule while other residues 
contact the TcR [16]. JanusMatrix, a new bioinformatics tool, interrogates a potential T cell epitope 
from both its HLA-binding and TcR-facing aspects, and assesses TcR cross-reactivity with T cell 
epitopes encoded by other genomes [13,14]. Those epitopes from two different genomic sources, 
e.g., HCV and human, that bind the same HLA molecules and present identical amino acids to the 
TcR are designated potentially cross-reactive, capable of stimulating the same TcR and triggering the 
same T cells to respond. In the analysis undertaken here, JanusMatrix divided the HCV HLA-DRB1-
restricted epitopes (comprising the ICS described above) into TcR-facing and MHC-binding amino 
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acid residues. The human protein database (UniProtKB) was then searched for TcR-facing epitopes 
that cross-react with the HCV epitopes.  
HLA-DRB1-restricted epitope selection, peripheral blood mononuclear cell (PBMC) culture, flow 
cytometric and statistical analyses. 
Detailed descriptions are provided in Supplementary Materials. 
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Results  
A peptide sequence in HCV p7 exhibits human homology 
Sustained, virus-specific CD4 and CD8 T cell responses are associated with successful control of 
HCV infection. Therapeutic vaccination offers a rational approach to stimulating host resistance and 
overcoming viral persistence in cases of chronic disease. Toward this end, 20 promiscuous HCV 
(genotype 1) ICS, each predicted to contain multiple T cell epitopes, were synthesized and validated 
by demonstrating their ability to bind a panel of the eight common alleles HLA-DRB1 alleles: 
DRB1*0101, *0301, *0401, *0701, *0801, *1101, *1301, and *1501, representing essentially the entire 
human population [17,18]. One highly conserved ICS, found in >90% genotypes 1a and 1b isolates 
and located within HCV p7 protein (HCV_G1_p7_794; WPLLLLLLALPQRAYAQ), exhibited significant 
human homology (>70% shared identities) determined by GenBank BLAST analysis; none of the 
remaining ICS exhibited the same homology.   
HCV_G1_p7_794 induces a CD3+CD4+FoxP3+ T cell response in HCV-infected patients  
A series of experiments was undertaken to determine and compare the HCV_G1_p7_794-specific 
responses of PBMCs obtained from non-infected control individuals (Ab-VL-), patients who 
spontaneously cleared HCV infection (Ab+VL-) and infected patients in whom viremia persisted 
(Ab+VL+). HCV_G1_p7_794 induced a marked increase in CD3+CD4+FoxP3+ cells when added to 
PBMC cultures derived from infected, Ab+VL+ patients (Figure 1A). In contrast, HCV_NS4B_1941 
(AARVTQILSSLTITQLLKRLHQWI; an ICS that exhibits little human homology) failed to promote a 
comparable increase. Similarly, other highly conserved HCV ICS with negligible human homology 
(e.g., HCV_G1_NS4b_1769; ISGIQYLAGLSTLPGNPA) failed to elicit a CD3+CD4+FoxP3+ cell 
response (data not shown). CD3+CD4+FoxP3+ cells, induced by the addition of HCV_G1_p7_794 to 
Ab+VL+ PBMC cultures, expressed both CD25 (IL-2 receptor α chain, constituently expressed by Treg 
cells) and CD39, a cell ectonucleotidase associated with Treg cell function (Figure 1B) [6,19].  
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While a significant increase in CD3+CD4+FoxP3+ cells was determined in PBMC cultures 
derived from HCV-infected patients, neither HCV_G1_p7_794 nor the control peptide 
(HCV_G1_NSB4_1941) added to PBMC cultures derived from non-infected individuals or from 
patients who spontaneously cleared HCV infection induced an increase (Figure 2A). Notably, Ab+VL+ 
patients had a higher baseline level of CD3+CD4+Foxp3+ cells compared to clearers or non-infected 
controls, a finding consistent with the literature [20].  
HCV_G1_p7_794 activates cross-reactive nTreg cells  
A human analog of HCV_G1_p7_794 (p7_794, PLLLLLLSLPPRA), identified by GenBank BLAST 
analysis, was synthesized in an effort to provide a clearer understanding of the nature of the Treg cells 
that respond to HCV_G1_p7_794. Like the HCV-encoded homolog, the human analog induced a 
significant increase in CD3+CD4+FoxP3+ cells in PBMC cultures derived from patients with persistent 
viremia (Figure 2B). In contrast to HCV_G1_p7_794, however, the human analog also induced an 
approximate three-fold increase in CD3+CD4+FoxP3+ cells in PBMC cultures derived from non-
infected (Ab-VL-) individuals, indicative of the capacity to elicit an nTreg cell response.  
HCV_G1_p7_794 suppresses the mitogenic response of T cells to anti-CD3 and IL-2 treatment  
The hallmark of CD3+CD4+FoxP3+ Treg cells is suppressor activity. The addition of HCV_G1_p7_794 
to Ab+VL+ PBMC cultures resulted in a modest, albeit reproducible, decrease in the proliferative 
response to anti-CD3 monoclonal antibody treatment assessed in terms of a loss in CFSE staining 
intensity (Figure 3A). Similar results were obtained when [3H]-thymidine incorporation was used to 
monitor cell proliferation, i.e., reduced proliferation in response to either anti-CD3 or IL-2 in those 
cultures that contained HCV_G1_p7_794 (Figure 3B). Importantly, the addition of HCV_G1_p7_794 
alone (in the absence of anti-CD3 or IL-2) had no effect on the proliferation of CD3+CD4+ T cells 
obtained from these same patients. This latter finding indicates that HCV_G1_p7_794 induces the 
conversion of conventional CD3+CD4+FoxP3- T cells to CD3+CD4+FoxP3+ iTreg cells (i.e., infectious 
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tolerance) rather than stimulates the proliferation of Treg cells already present. An increase in 
CD3+CD4+FoxP3+ Treg cells that lack cell-surface neuropilin-1 supports this suggestion. 
CD304 (neuropilin-1) is expressed by a subset of FoxP3+ Treg cells in humans [21]. In mice, 
CD304 expression differentiates natural (CD304+), from inducible (CD304-), Treg cells [22]. While a 
similar distinction has yet to be reported in humans, it is pertinent to note that the bulk of 
CD3+CD4+FoxP3+ cells contained among Ab+VL+ PBMCs cultured in the absence of 
HCV_G1_p7_794 expressed CD304 indicative of nTreg cells (Figure 4A). In contrast, the vast majority 
of CD3+CD4+FoxP3+ cells among Ab+VL+ PBMCs cultured in the presence of HCV_G1_p7_794 were 
CD304- characteristic of iTreg cells (Figure 4B). Taken together, these findings support our speculation 
that HCV_G1_p7_794 recognition by nTreg cells following HCV exposure promotes infectious 
tolerance and the production of FoxP3+ iTreg cells from conventional CD3+CD4+FoxP3- T cells. This 
contention is supported by experiments demonstrating the failure of HCV_G1_p7_794 to promote an 
increase in CD3+CD4+FoxP3+ cells among Ab+VL+ PBMCs depleted of constitutive, CD25-expressing 
(nTreg) cells prior to culture (Supplementary Figure 1). 
JanusMatrix confirms Treg cell epitopes shared by HCV_G1_p7_974 and the human proteome    
By comparing HCV G1_p7_794 with peptide sequences found in the human proteome, JanusMatrix 
analysis provided further insight into the capacity of HCV_G1_p7_794 to induce a Treg cell response 
by PBMCs derived from HCV-infected patients. As illustrated in Table 2, HCV_G1_p7_794 contains 
five T cell epitopes, which cross-react with 152 putative human T cell epitopes contained in 264 
different human proteins. Similarly, the human analog, p7_794, cross-reacts with putative T cell 
epitopes located within several hundred human proteins. In contrast, neither HCV_G1_NS4b_1941 
(control ICS often used in the ex vivo experiments described above) nor any of the 18 other putative 
ICS, validated by their ability to elicit immune recognition and IFN-γ production by naïve human T 
cells ex vivo [17], exhibited significant cross-reactivity with the human proteome. Moreover, 
HCV_G1_p7_794 induced substantially fewer naïve T cells to produce  IFN-γ assessed by ELISpot 
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assay, i.e., 64 + 75 versus 655 + 591 (mean ± SD number of spots/106 T cells, n=8) for 
HCV_G1_p7_794 and HCV_G1_NS4b, respectively; values are significantly different (p=0.021; 
Mann-Whitney rank sum test). The relative inability to induce IFN-γ production supports our 
speculation that, rather than activate Teff cells, HCV_G1_p7_794 activates a cross-reactive nTreg cell 
population that normally functions to suppress autoimmune responses to a large number of human 
proteins, which contain a common peptide sequence (epitope).  
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Discussion 
Resolution of primary HCV infections is dependent upon the vigorous response of CD4+ and CD8+ T 
cells to multiple viral epitopes [23]. HCV persists in the majority of infected patients, however, by 
modifying and/or evading the host immune response.  Purportedly, a variety of factors contribute to 
the diminished T cell responses observed in chronically infected patients including: viral mutation and 
escape linked to both CD4 and CD8 T cell failure, CD4 T cell anergy, CD8 T cell exhaustion, impaired 
dendritic cell function, and Treg cell-mediated suppression [2,3,6,7,24,25]. The increased frequency of 
Treg cells found in the liver and circulating in the peripheral blood of chronically-infected patients, 
confirmed in the current study (Figure 2), provided an initial indication of the role of Treg cells in the 
pathogenesis of chronic hepatitis C [2,3,5,11]. It remained unclear until recently, however, whether 
this increase represented the HCV epitope-specific response of Treg cells or the nonspecific 
consequence of chronic inflammation and liver disease [7].    
The ability of HCV-derived epitopes to stimulate Treg cell responses is well documented; 
epitopes associated with both structural and non-structural HCV proteins have been reported [20,26].  
Using HLA class II-peptide tetramer complexes, other investigators quantified and characterized the 
response of Treg cell specific for single HCV epitopes [20,26]. The study described herein is the first, 
however, to identify a promiscuous HCV peptide sequence (HCV_G1_p7_794) that exhibits extensive 
human homology and the ability to elicit a Treg cell response in a wide, HLA-diverse human 
population, such as the infected patient population shown in Table I. Unlike the Treg cell epitopes 
described previously, HCV_G1_p7_794 is an ICS composed of multiple HLA binding motifs able to 
bind a number of DRB1 alleles. Unfortunately, this precludes construction of an HLA-peptide tetramer 
complex and quantitation of the HCV_G1_p7_794-responsive cells. In accord with the literature, 
HCV_G1_p7_794 added to PBMCs cultures derived from HCV-infected patients, but not non-infected 
individuals or patients who cleared infection, induced a marked increase in CD3+CD4+FoxP3+ cells 
[20,26]. In addition to expressing CD25, characteristic of Treg cells, the vast majority of these cells 
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expressed CD39, a marker that distinguishes FoxP3+ Treg cells from activated Teff cells that transiently 
express FoxP3 [6,19].  
In contrast to HCV_G1_p7_794, the human peptide analog (p7_794) elicited a significant 
increase in CD3+CD4+FoxP3+ cells in PBMC cultures derived from non-infected individuals with no 
evidence of prior HCV exposure, as well as HCV-infected patients. This finding is congruent with the 
suggestion that viral epitopes with human homology influence the pathogenesis of chronic HCV by 
activating preexisting, cross-reactive nTreg cells [11]. Indeed, extensive homology between the HCV 
polyprotein and proteins that comprise human proteome is well documented [27,28]. JanusMatrix, a 
bioinformatics algorithm that interrogates potential T cell epitopes from both their HLA-binding and 
TcR-facing aspects, confirmed the existence of significant homology between HCV_G1_p7_794 and 
proteins that compose the human proteome. The results of this analysis demonstrate the potential 
efficacy of JanusMatrix in identifying pathogen-encoded epitopes that elicit the activity of nTreg cells, 
which normally function to suppress autoimmune reactivity to self-antigens (proteins). In this regard, it 
is pertinent to remark that HCV_G1_p7_794 is comprised of epitopes that are homologous to those 
found in hundreds of human proteins. This suggests the autoimmune response to a large number of 
proteins is inhibited by a single or limited number of nTreg cell clones responsive to a common peptide 
sequence, rather than a large number of clones each responsive to a unique sequence in a single 
protein only. The oligoclonality of the Treg cell response to HCV_G1_p7_794 and its human analog is 
a matter of ongoing investigation. 
The majority of individuals in our patient population were infected with HCV genotype 1, the 
derivation of HCV_G1_p7_794. The addition of HCV_G1_p7_794 to PBMC cultures derived from a 
single HCV genotype 3-infected patient, however, also resulted in a marked increase in 
CD3+CD4+FoxP3+CD25+ cells (Supplementary Figure 2). It is pertinent to note, in this regard, that 
HCV genotype 3 encodes a peptide sequence: LALLVLLLPQRAYAW, which exhibits 
HCV_G1_p7_794 homology. 
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Conceivably, other viral pathogens that cause chronic disease, e.g., herpes simplex, Epstein-
Barr, human immunodeficiency and cytomegalovirus, also avoid or reduce Teff cell responses by 
exploiting similarity to self and activating nTreg cells [29,30]. Indeed, recent analyses indicated that 
Epstein-Barr virus and cytomegalovirus contained fewer T cell epitopes and exhibited higher cross-
reactivity with the human genome than did either Ebola or Marburg virus [14].  Ebola and Marburg 
viruses, on the other hand, were composed of significantly fewer peptide sequences that were cross-
reactive with human and expressed a larger number of predicted T cell epitopes. Thus, viruses that 
cause acute disease and viruses such as HCV, which adapt to humans and cause chronic infection, 
may differ substantially in terms of their Treg cell epitope content.  
Although immunosuppression by Treg cells is readily demonstrated in mice, demonstrating the 
suppressor activity of human CD3+CD4+CD25+FoxP3+ Treg cells has proven problematic [31]. Recent 
studies indicate that the nature of the responder T cells (CD4+CD25- versus CD4+CD25low) and the 
ratio of Treg cells to responder cells exert significant effects on the outcome of suppression assays 
[32,33]. Nonetheless, the HCV_G1_p7_794 responsive Treg cells suppressed the mitogenic response 
of cells derived from HCV infected patient in the experiments reported here despite the fact that the 
CD3+CD4+FoxP3- responder cells far outnumbered CD3+CD4+CD25+FoxP3+ suppressor cells among 
total PBMCs by a greater than 10:1 ratio,  
Notably, the addition of HCV_G1_p7_794 alone to PBMC cultures derived from HCV-infected 
(Ab+VL+) patients failed to induce cell proliferation despite a marked (3- to 4-fold) increase in 
CD3+CD4+CD25+FoxP3+ cell number. This finding indicates that HCV_G1_p7_794 induces the 
conversion of conventional CD4+FoxP3- T cells to Treg cells, i.e., infectious tolerance, a suggestion 
supported by studies demonstrating the inability of nTreg cells to proliferate in response to their 
cognate antigen in vitro [34]. Furthermore, in contrast to Ab+VL+ PBMCs cultured in medium alone, 
only a minority of CD3+CD4+FoxP3+ cells cultured in the presence of HCV_G1_p7_794 expressed 
CD304 (neuropilin), which is expressed by a subset of FoxP3+ Treg cells in humans and associated 
specifically with nTreg cells in mice [21,22]. While it has been suggested alternatively that the 
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expanded Treg cell population in chronic, HCV infected patients is composed of cells phenotypically 
similar to nTreg or iTreg cells [11,20], our results concur with the consensus that the expanded Treg cell 
population in chronic HCV-infected patients is heterogeneous, composed of both Treg cell subsets.   
HCV p7, a 63-amino acid polypeptide chain that spans the endoplasmic reticulum membrane of 
infected cells, is essential for viral replication [35]. Hydrophobicity is a common characteristic of 
hepatitis C viral epitopes [36]. As such, the hydrophobic nature of HCV_G1_p7_794 is unlikely to 
account for the disparate responses of CD3+CD4+FoxP3+ Treg cells in infected and non-infected 
individuals. Moreover, while glycosylation can impair T cell recognition [36], there is no evidence to 
suggest that HCV p7 is glycosylated or that glycosylation affects the differential response to 
HCV_G1_p7_794. Indeed, the same non-glycosylated synthetic peptide (HCV_G1_p7_794) added to 
cultures of infected and non-infected PBMCs elicited different outcomes. Rather, the findings reported 
herein suggest that HCV_G1_p7_794 is a unique peptide sequence recognized by nTreg cells that 
function normally to suppress the autoimmune response to hundreds of human proteins that contain 
the p7_794 sequence. Upon HCV_G1_p7_794 recognition, these nTreg cells induce the conversion of 
conventional T cells to iTreg cells (i.e. infectious tolerance).  We speculate that the nTreg cells and iTreg 
cells responsive to HCV_G1_p7_794 contribute to the elevated Treg cell population found in HCV-
infected patients, and play a role in immunosuppression and viral persistence.  
The mechanism(s) that underlies the elevated Treg cell response to HCV_G1_p7_794 observed 
in HCV-infected, but not non-infected, individuals remains to be determined. We hypothesize, 
however, that dysfunctional interaction with antigen-presenting cells is involved. Most studies indicate 
that DCs are functionally impaired in patients with chronic hepatitis C [6,37]. Impairments include: 
decreased IFN-α and IL-12 secretion, lowered expression of co-stimulatory molecules (CD80 and 
CD86) and an increased ability to prime Treg cells. In addition, a recent report suggests that B cells 
contribute to the increase in Treg cells associated with chronic hepatitis C [38]. Indeed, naïve pan T 
cells co-cultured with purified CD19+ B cells in the presence of HCV_G1_p7_794, but not 
HCV_G1_NS4b_1941 or medium alone, exhibited a marked (3-4-fold) increase in CD3+CD4+FoxP3+ 
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cells (Supplementary Table I). Notably, the HCV_G1_p7_794 responsive cells were phenotypically 
consistent with iTreg cells expressing neither CD304 nor Helios, markers associated with nTreg cells 
[21,22,39]. The potential contribution of APCs to the disparate T cell responses to HCV_G1_p7_794 
observed in HCV-infected and non-infected individuals is illustrated in the schematic shown in 
Supplementary Figure 3. The ex vivo systems described herein enable detailed analyses of the 
mechanisms that underlie the generation and function of these HCV_G1_p7_794 responsive cells.  
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Table I.  Human Subjects  
Subject ID#  Age  HCV Status Viral Load IU/ml Genotype     Antibody     HLA-DRB1 
 229 28  Infected   170,620   1 + 03,11 
 236 29  Infected   602,611   1 + 01,11 
 260  28   Infected 1,410,524 3 + 03,07 
 261  25   Infected      7,464,611   1 + 01,11 
 265        22   Infected  21,917,190 1a + 13,15 
 272  23    Infected  458 1a + 03,11 
 279   25    Infected   1,788,326 1a + 13,15 
 282   28   Infected     86,678 1a + 03,04 
 216   23   Clearer   NA  NA + 07:01 
 221  27    Clearer   + 03,11 
 222  25   Clearer   + 03,15 
 246  26  Clearer   + 01,04 
 267  23  Clearer   + 03,11 
 264  27  Clearer   + 03,11 
 248  26  Non-infected    - 04,11 
 259  26  Non-infected    - 04,11 
 262  22  Non-infected    - 03,11 
 257  22  Non-infected    - 03,15 
 263  26  Non-infected     - 01,03 
NA = not applicable/available. 
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Table II.  JanusMatrix Analysis 
 
   # Cross-reactive  # Human Proteins 
Description  ICS Epitopes per ICS  containing Cross- 
    reactive Epitopes 
 
HCV_G1_p7_794a  WPLLLLLLALPQRAYAQ     5.0 264 
 
Human p7_794b  PLLLLLLSLPPRA    4.0 325 
HCV_G1_NS4b_1941c  AARVTQILSSLTITQLLKRLHQWI    6.0 28 
aHuman homolog; highly conserved sequence derived from hepatitis C virus, genotype 1. 
bAnalog; sequence found in multiple human proteins. 
cValidated promiscuous, Teff cell ICS derived from hepatitis C virus, genotype 1 [17]. 
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Figure Legends  
Fig. 1.  HCV_G1_p7_794 induces the production of CD3+CD4+FoxP3+ cells in cultures of 
PBMCs derived from HCV-infected patients. PBMCs were cultured in the presence of medium 
alone, 10 µg/ml HCV_G1_p7_794 or 10 µg/ml HCV_G1_NS4b_1941.  Cells collected after 5 days 
incubation were analyzed by flow cytometry (A). The CD3+CD4+FoxP3+ cells were further 
characterized by the expression of CD25 and CD39 where the dotted line represents the isotype 
control (B). The gating scheme and representative analyses are shown. 
Fig. 2.  HCV_G1_p7_794 fails to elicit an increase in CD3+CD4+FoxP3+ cells among PBMCs 
derived from non-infected individuals. PBMCs obtained from infected patients (Ab+VL+, n= 4), 
patients who clear infection (Ab+VL-, n= 6) and non-infected controls (Ab-VL-, n= 4) were cultured with 
medium alone, HCV_G1_p7_794 or HCV_G1_NS4b_1941 (A). The cells collected after 5 days were 
analyzed by flow cytometry. *Significantly different: *P=0.014; **P<0.001.  
PBMCs obtained from Ab+VL+ patients (n= 4) and Ab-VL- controls (n= 4) were cultured in the 
presence or absence of the human p7_794 analog (B).  Significantly more CD3+CD4+FoxP3+ cells 
were recovered from  PBMC cultured with the analog than medium alone: *P=0.001; **P=0.048.  
Fig. 3. HCV_G1_p7_794 suppresses the proliferation of PBMCs derived from HCV-infected 
patients. CSFE-labeled, Ab+VL+ PBMCs were cultured with medium alone, or medium containing 
anti-CD3, HCV_G1_p7_794, or anti-CD3 and HCV_G1_p7_794. Cells were collected after 5 days; 
proliferation was estimated by flow cytometry and a loss in fluorescence intensity. Data were obtained 
in a single experiment representative of two HCV-infected patients (A). PBMCs obtained from the 
three patients listed were cultured 5 days in the presence of anti-CD3 or 20 ng/ml IL-2 with or without 
HCV_G1_p7_794; cell proliferation was estimated by [3H-thymidine incorporated during the last 18 
hours of incubation (B).  
  
 
25  
Fig. 4.  Fewer HCV-G1_p7_794-responsive Treg cells express CD304 (neuropilin).  PBMCs 
obtained from an infected patient (representative of 4 patients) were incubated in medium alone (A) 
or medium that contained HCV_G1_p7_794 (B).  The cells were collected on day 5, stained and 
analyzed by flow.  Panels on the right indicate the percentage of CD4+FoxP3+ cells in each population 
that expresses CD304.  
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Figure 3 
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Materials and Methods 
HLA-DRB1-restricted epitope selection 
HCV sequences were acquired from the Los Alamos database [1,2]. Nine-mer amino acid 
sequences, capable of fitting the binding groove of HLA class II molecules and highly conserved 
across HCV genotype 1a and 1b isolates, were identified and scored for potential to bind eight 
common HLA class II (DRB1) alleles using bioinformatics tools [3-5]. HLA class II immunogenic 
consensus sequences (ICS) were identified and constructed by assembling potentially immunogenic 
9-mers into 18-25 amino acid sequence [3]. ICS construction improves the probability that an epitope 
will be presented in the context of more than one HLA allele, thus broadening the response of an 
HLA-diverse human population. Twenty ICS derived from HCV genotypes 1a and 1b were 
synthesized as peptides using 9-fluoronylmethoxycarbonyl chemistry and purified >85% by 21st 
Century Biochemicals (Marlboro, MA).  Each of these “promiscuous” ICS contained between 5 and 
28 predicted HLA binding motifs, and were bound by multiple HLA-DRB1 alleles in competitive 
binding assays as described previously [6,7]. Each ICS was also evaluated for human homology (>7 
shared identities per 9-mer frame) using GenBank BLAST [8]. 
Peripheral blood mononuclear cell (PBMC) cultures   
Cryopreserved PBMCs from participating subjects were thawed; suspended in HEPES-buffered 
RPMI1640 medium supplemented with 10% HuAB serum (Valley Biomedical, Winchester, VA), 
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin; and rested overnight at 37oC in a 
humidified, CO2 incubator. On the following day, the PBMCs were centrifuged and resuspended in 
fresh medium containing 5% HuAB serum; 1 x 106 cells/ml were transferred to deep, flat-bottom, non-
treated 48-well plates. The peptide sequence indicated in the text was added (10 µg/ml final 
concentration) and the cells were incubated for 5 days. PBMCs cultured in the presence of medium 
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with 0.1% DMSO served as a negative control. Half the spent medium was replaced on day 3.  The 
cells were collected for analysis on day 5.   
For proliferation assays, cells rested overnight were labeled with carboxyfluorescein diacetate, 
succinimidyl ester (CFSE: Life Technologies Corporation, Carlsbad, CA) prior to culture in the 
presence or absence of 10 µg/ml HCV_G1_p7_794,10 µg/ml human p7_794 or 30 ng/ml anti-CD3 
monoclonal antibody (clone HIT3a; BioLegend, San Diego, CA). Cell proliferation was evaluated by 
flow cytometric analysis according to the protocol provided by Life Technologies in which a loss in 
fluorescence intensity correlates directly with the extent of replication. Alternatively, non-CSFE-
labeled cells were pulsed with 0.1 µCi [3H]-thymidine during the last 18 hours of the 5-day culture 
period; radiolabeled-thymidine incorporation was quantified by liquid scintillation counting. 
Flow cytometry   
Stimulated PBMC were quantified and characterized in accordance with methods we described 
previously [9]. The following dye-conjugated mouse monoclonal antibodies were purchased from 
BioLegend (San Diego, CA) and used: CD3, CD4 (clone OKT4), CD8a (clone HIT8a); CD39 (clone 
A1), and CD304 (clone 14H4); anti-human CD25 (clone M-A251) and anti-human FoxP3 (clone 236a) 
were purchased from BD Biosciences (San Jose, CA). Data were collected on a BD LSRII Flow 
Cytometer (BD Biosciences, San Jose, California) and analyzed using FlowJo software (Tree Star, 
Inc., Ashland, OR). All analyses were conducted using the appropriate isotype controls to correct for 
non-specific staining.   
Statistical Analysis  
The results were analyzed using the SigmaStat statistics program (Aspire Software International).  
Means were compared using a non-paired Student's t test or a Mann-Whitney Rank Sum test.  
Aggregate data were compared by one-way analysis of variance; the Dunnett’s test determined which 
groups differed significantly.   
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Supplementary Fig. 1. CD25+ cell depletion prior to culture abrogates the Treg cell response to 
HCV_G1_p7_794.   
PBMCs obtained from the two HCV-infected patients indicated were either depleted or not depleted 
of CD25 expressing cells using antibody-coated magnetic beads (Miltenyi Biotech, Auburn, CA). 
Depleted (CD25-) and non-depleted (CD25+) PBMCs were cultured in the presence or absence of 
medium that contained 10 µg/ml HCV_G1_p7_794. The cells were collected after 5 days incubation 
and the CD3+CD4+FoxP+ T cells were quantified by flow cytometry. 
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Supplementary Fig. 2. HCV_G1_p7_794, derived from HCV genotype 1, induces the production 
of CD3+CD4+FoxP3+ cells in cultures of PBMCs obtained from an HCV genotype 3 infected 
patient. PBMCs were cultured in the presence of medium alone, HCV_G1_p7_794, 
HCV_G1_NS4b_1941 or human p7_794 analog. Cells collected after 5 days incubation were 
analyzed by flow cytometry. 
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Supplementary Fig. 3. Schematic: HCV_G1_p7_794 presentation by B cells or impaired DCs 
promotes infectious tolerance, loss of anti-viral Teff cell activity and persistent HCV infection.  
During the normal course of protein turnover, mature antigen presenting cells (APCs) process and 
present the p7_794 sequence in hundreds of distinct self-proteins. Immune recognition and the 
activity of p7_794-specific CD3+CD4+FoxP3+CD304+ nTreg cells suppress the autoimmune response 
of Teff cells specific for the same self-proteins (A). In HCV-infected patients, HCV_G1_p7_794 
presented by B cells or impaired (phenotypically immature) DCs induces the epitope-specific 
response of nTreg cells and the subsequent conversion of conventional (CD3+CD4+FoxP3-) T cells to 
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CD3+CD4+FoxP3+CD304+ iTreg cells. iTreg cells, in turn, block the anti-viral response of Teff cells 
specific for HCV_G1_p7_794, as well as other viral epitopes (bystander suppression) (B).  
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Table I. HCV_G1_p7_794 induces CD3+CD4+FoxP3+ cells in co-cultures composed of purified, 
naïve human T cells and B cells   
  0.1% DMSO  HCV_G1_p7_794    HCV_G1_NS4b_1941 
 FoxP3+a    2.12   7.76   2.23  
 CD39+b 94.65 99.00 96.09 
 CD152+b    0.63   0.55   1.29 
 CD304+b 61.01 37.99 61.49 
 HELIOS+b    3.16   1.61   4.78 
 
CD19+ B cells and pan-T cells were purified from the PBMCs of a normal blood donor using magnetic 
beads (Miltenyi Biotec). Equal numbers were suspended in X-VIVO 15 medium (Lonza, Walkerville, 
MD) supplemented with glutamine, penicillin, streptomycin, and 50 U/ml recombinant human IL-2 
(Roche Applied Science, Indianapolis, IN) and subsequently co-cultured in the presence of 0.1% 
DMSO, 10 µg/ml HCV_G1_p7_794 or 10 µg/ml HCV_G1_NS4b_1941. The cells were collected after 
14 days incubation and the CD3+ cells were phenotyped by flow cytometry. Data are the results of a 
single experiment representative of two identical experiments.   
aPercentage of CD3+CD4+ cells. 
bPercentage of FoxP3+ cells. 
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